1. Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances;Pierson;Org. Process Res. Dev.,2009
2. Application of the principles of the ICHM7 guideline to calculation of compound-specific acceptable intakes Addendum to M7(R2) October 2021. ICH_M7R2_Guideline-Addendum_Step2_ForPublicConsultation_2021_1006_1.pdf.
3. Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches, United States Department of Health and Human Services, Food and Drug Administration, 2008 E8-29674.pdf (govinfo.gov).
4. USFDA, Guidelines for Industry; Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches (Draft), December 2008 https://www.federalregister.gov/documents/2008/12/16/E8-29674/draft-guidance-for industry on-genotoxic-and-carcinogenic-impurities-in-drug-substances-and-products.
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, S2 (R1),2011, https://database.ich.org/sites/default/files/S2_R1_Guideline.pdf.